Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)

Posted on by

SHANGHAI, Dec. 13, 2023 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”) today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation (“FTD”) by the U.S. FDA for the treatment of tenosynovial giant cell tumor (“TGCT”)…